TATVABSETatva Chintan Pharma Chem LtdMediumNeutral
Announced Sat, 16 May · 15:50 IST

Investor Presentation for the quarter and financial year ended 31 March 2026.

Investor Communications View source PDF

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹1334.90
prior close
₹1300.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.7-6.3-6.3-3.7-6.6-11.3-10.9-11.2-13.9-12.8-9.4+28.4
Up moveDown movePending
AI summary

Tatva Chintan reported strong financial recovery in FY26 with revenue up 32% to Rs 5,059 Mn from Rs 3,827 Mn in FY25. EBITDA surged 172% to Rs 932 Mn with margin expanding from 8.9% to 18.4%. PAT jumped 636% to Rs 421 Mn versus Rs 57 Mn, translating to EPS of Rs 17.98 vs Rs 2.44. Q4FY26 also showed robust growth with revenue at Rs 1,341 Mn (up 24% YoY) and EBITDA at Rs 281 Mn (up 214% YoY). Revenue mix shifted with SDA growing to 41% of revenue, PASC at 32%, and PTC at 23%. The company attributes recovery to improved operational efficiency and higher utilization. Note: This filing contains actual results data, not forward-looking guidance.

Likely market impact

Strong turnaround from FY25's compressed margins; however, Q4 PAT declined 32% sequentially which may concern near-term investors. The stock may see positive reaction given the dramatic margin recovery and profit growth, though forward guidance would be needed for sustained positive sentiment.